Friday, 19 Jul 2019

Biologic/Novel Rx

Datesort ascending Type Title Save
01 Oct 2018 Social Hear nine experts talk about biosimilars in Therapeutic Update: Biosimilars, a video series brought to viewers by Sandoz. Now available on RheumNow. https://t.co/xyqelyCd2r #sponsored #biosimilars
29 Sep 2018 Social RheumNow Week in Review is up! I wanna new Drug - Ustekinumab? https://t.co/8573kuWwxO or listen at iTunes or here https://t.co/HMMA8mQ0ue
25 Sep 2018 Social Mylan and Fujifilm have won a European Commission approval to market their Humira biosimilar called Hulio. That makes for 5 such adalimumab biosimilars (others from Amgen, Sandoz, Samsung Bioepis, Boehringer Ingelheim) https://t.co/KlgPjxhU6I
20 Sep 2018 News Unproven But Profitable Stem Cell Clinics
17 Sep 2018 Social Dermatology (EADV) Congress in Paris reports 24 wk trial results of a JAK3 inhibitor and TYK2/JAK1 inhibitor in patients with alopecial areata. The 24 wk placebo-adjusted mean improvements were 33.6 and 49.5 points (P<0.0001), evident as early as Week 6, https://t.co/zN2aGpHXWk
14 Sep 2018 Social FDA approves SC Actemra (tocilizumab) for systemic JIA (Still's disease) +/-MTX. IV TCZ was FDA approved In 2011 for SJIA. Approval is based on JIGSAW, a 52-wk study. sJIA dosing based on Weight ( <30 kg-162 mg q2wk; ≥30 162 mg qwk) https://t.co/kWXdwAh35Z
11 Sep 2018 News Out of Pocket Costs for Biosimilars - No Savings So Far
11 Sep 2018 News Cutting Oral JAK 1/2 Inhibitor Dose an Option in RA
04 Sep 2018 News Tocilizumab Equals other Biologics in Cardiovascular Risk
30 Aug 2018 Slide of the day Still's Disease Survey Results: July 2018
30 Aug 2018 News Treatment Preferences in Still’s Disease
30 Aug 2018 Social Innate immune responses induced by GM-CSF induction of NLRP3 expression and IL-1β production by neutrophils can be blocked by tofacitinib. Could tofacitinib be effective in Still's disease and other autoinflammatory disorders? https://t.co/1eynwIbl6d
28 Aug 2018 News Questions Remain about Shingrix Safety in Rheumatic Disease
13 Aug 2018 News Success of Stopping Depends on the Biologic
06 Aug 2018 Social Psoriasis biologic pipeline continues to grow. In development are IL-23 inhibitors (risankizumab, mirikizumab) & the IL-17 A/F inhbitor (bimekizumab). Tildrakizumab and certolizumab were approved for Psoriasis earlier in 2018. https://t.co/QFbdtO1Lua
04 Aug 2018 Social Switching to biosimilars (and generics) saved the UK National Health Service NHS England saved £324 million in 2017/2018. https://t.co/WxpWYAt3bh
02 Aug 2018 Social Pfizers announces EU approval for tofacitinib 10 mg bid for use in adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response or intolerance to DMARD or biologic agents https://t.co/Cw9JFozphJ
01 Aug 2018 Social Positive Results from Phase III study of RHB-104 in Crohn’s Disease; RHB-104 is a combo antimycobacterial-antibiotic with antiinflammatory properties (given w/ hypothesis that CD caused by a mycobacterium avium paratuberculosis https://t.co/w78xCKkAlG
01 Aug 2018 News IL-1 Suppression May Improve Dilated Cardiomyopathy
31 Jul 2018 Social EMA's CHMP has recommended approval of the IL-23 inhibitor tildrakizumab (Ilumetri, Almirall) for adults with moderate - severe plaque psoriasis. (Based on reSURFACE1 and reSURFACE2 RCTs w/ >80% PASI 75 responses. https://t.co/Qm0qIgAJ2G